[Mycobacterial antigens and tuberculosis antibodies in the blood and pleural exudate of patients with tuberculous pleurisy].
To enhance the efficiency of treating tuberculous pleurisy, a complex of therapeutical measures was supplemented by the immunomodulator licopid in 51 patients. The control group included 52 patients with pleurisy who received the same treatment regimen without licopid. Comparing the outcomes of treatment has revealed that licopid reduced the time of treatment, promotes the substantial diminution of antigenemia and the production of tuberculosis antigens, improves cell immunity and natural resistance.